Do analysts rate GRI or HEPA?

GRI Bio currently has a consensus target price of $32.00, indicating a potential upside of 1,575.39%. Given GRI Bio's stronger consensus rating and higher possible upside, research analysts plainly believe GRI Bio is more favorable than Hepion Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GRI Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, GRI or HEPA?

GRI Bio is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRI Bio N/A N/A -$11.96M -$38.37 N/A Hepion Pharmaceuticals N/A N/A -$48.93M -$72.15 N/A

Is GRI or HEPA more profitable?

GRI Bio's return on equity of -134.03% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets GRI Bio N/A -134.03% -106.83% Hepion Pharmaceuticals N/A -812.56% -207.31%

Do analysts recommend HEPA or SXTP?

60 Degrees Pharmaceuticals has a consensus price target of $13.85, indicating a potential upside of 1,182.41%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Hepion Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 60 Degrees Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer HEPA or NXTS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Nexentis Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HEPA or NXTS more profitable?

Nexentis Technologies' return on equity of -304.79% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Hepion Pharmaceuticals N/A -812.56% -207.31% Nexentis Technologies N/A -304.79% -178.91%

Is VCNX or HEPA more profitable?

Vaccinex's return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% Hepion Pharmaceuticals N/A -812.56% -207.31%

Hepion Pharmaceuticals (HEPA) Competitors

$0.06 -0.01 (-12.16%)

As of 08/26/2026 12:20 PM Eastern

Compare

HEPA vs. GRI, SXTP, NXTS, VCNX, and CASI

Should you buy Hepion Pharmaceuticals stock or one of its competitors? Hepion Pharmaceuticals's main competitors and comparable companies include GRI Bio (GRI), 60 Degrees Pharmaceuticals (SXTP), Nexentis Technologies (NXTS), Vaccinex (VCNX), and CASI Pharmaceuticals (CASI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Hepion Pharmaceuticals compare to GRI Bio?

GRI Bio (NASDAQ:GRI) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

34.0% of GRI Bio shares are held by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 8.7% of GRI Bio shares are held by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

GRI Bio's return on equity of -134.03% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-134.03%	-106.83%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

GRI Bio currently has a consensus target price of $32.00, indicating a potential upside of 1,575.39%. Given GRI Bio's stronger consensus rating and higher possible upside, research analysts plainly believe GRI Bio is more favorable than Hepion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

GRI Bio is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96M	-$38.37	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

In the previous week, GRI Bio had 4 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 4 mentions for GRI Bio and 0 mentions for Hepion Pharmaceuticals. GRI Bio's average media sentiment score of 0.96 beat Hepion Pharmaceuticals' score of 0.00 indicating that GRI Bio is being referred to more favorably in the media.

Company	Overall Sentiment
GRI Bio	Positive
Hepion Pharmaceuticals	Neutral

GRI Bio has a beta of -1.21, meaning that its stock price is 221% less volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

Summary

GRI Bio beats Hepion Pharmaceuticals on 11 of the 13 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to 60 Degrees Pharmaceuticals?

Hepion Pharmaceuticals (NASDAQ:HEPA) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Hepion Pharmaceuticals has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.54, indicating that its share price is 154% more volatile than the broader market.

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Hepion Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 0.57 beat Hepion Pharmaceuticals' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Hepion Pharmaceuticals	Neutral
60 Degrees Pharmaceuticals	Positive

17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

60 Degrees Pharmaceuticals has a consensus price target of $13.85, indicating a potential upside of 1,182.41%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Hepion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

60 Degrees Pharmaceuticals has higher revenue and earnings than Hepion Pharmaceuticals. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A
60 Degrees Pharmaceuticals	$1.41M	2.70	-$7.36M	-$4.82	N/A

Hepion Pharmaceuticals has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -650.21%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%
60 Degrees Pharmaceuticals	-650.21%	N/A	-136.81%

Summary

60 Degrees Pharmaceuticals beats Hepion Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Nexentis Technologies?

Hepion Pharmaceuticals (NASDAQ:HEPA) and Nexentis Technologies (NASDAQ:NXTS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

In the previous week, Nexentis Technologies had 1 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 1 mentions for Nexentis Technologies and 0 mentions for Hepion Pharmaceuticals. Nexentis Technologies' average media sentiment score of 1.87 beat Hepion Pharmaceuticals' score of 0.00 indicating that Nexentis Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Hepion Pharmaceuticals	Neutral
Nexentis Technologies	Very Positive

Hepion Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market. Comparatively, Nexentis Technologies has a beta of 1.83, meaning that its share price is 83% more volatile than the broader market.

17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.2% of Nexentis Technologies shares are owned by institutional investors. 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Comparatively, 6.5% of Nexentis Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nexentis Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nexentis Technologies' return on equity of -304.79% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%
Nexentis Technologies	N/A	-304.79%	-178.91%

Nexentis Technologies has higher revenue and earnings than Hepion Pharmaceuticals. Nexentis Technologies is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A
Nexentis Technologies	$210K	12.98	-$4M	-$96.07	N/A

Summary

Nexentis Technologies beats Hepion Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Vaccinex?

Vaccinex (NASDAQ:VCNX) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

Vaccinex has higher revenue and earnings than Hepion Pharmaceuticals. Vaccinex is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	4.80	-$20.25M	-$48.27	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

Vaccinex has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

Vaccinex's return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

50.1% of Vaccinex shares are held by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 51.5% of Vaccinex shares are held by company insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Vaccinex's average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Vaccinex	Neutral
Hepion Pharmaceuticals	Neutral

Summary

Vaccinex beats Hepion Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to CASI Pharmaceuticals?

CASI Pharmaceuticals (NASDAQ:CASI) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

In the previous week, CASI Pharmaceuticals' average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Hepion Pharmaceuticals	Neutral

CASI Pharmaceuticals currently has a consensus target price of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe CASI Pharmaceuticals is more favorable than Hepion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

CASI Pharmaceuticals has higher revenue and earnings than Hepion Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

CASI Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

Hepion Pharmaceuticals has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

Summary

CASI Pharmaceuticals beats Hepion Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

Get Hepion Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HEPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HEPA vs. The Competition

Export

Metric	Hepion Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$743K	$12.65B	$7.38B	$12.81B
Dividend Yield	N/A	2.61%	2.53%	11.02%
P/E Ratio	-0.01	783.00	272.19	24.11
Price / Sales	N/A	791.71	594.71	74.77
Price / Cash	N/A	96.46	79.89	53.65
Price / Book	0.05	12.04	13.06	6.20
Net Income	-$48.93M	$2.83B	$3.47B	$348.07M
7 Day Performance	N/A	1.87%	1.88%	1.02%
1 Month Performance	N/A	5.71%	8.06%	4.20%
1 Year Performance	N/A	7.44%	26.03%	16.46%

Hepion Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HEPA Hepion Pharmaceuticals	N/A	$0.07 -12.2%	N/A	-0.9%	$743K	N/A	N/A	20	Upcoming Earnings
GRI GRI Bio	2.6803 of 5 stars	$1.73 +1.2%	$32.00 +1,749.7%	-95.2%	$3.06M	N/A	N/A	1
SXTP 60 Degrees Pharmaceuticals	2.5481 of 5 stars	$1.13 +0.9%	$13.85 +1,125.7%	-78.7%	$3.01M	$1.00M	N/A	3
NXTS Nexentis Technologies	0.6516 of 5 stars	$1.91 -3.5%	N/A	-96.5%	$2.77M	$210K	N/A	2	Positive News
VCNX Vaccinex	N/A	$1.00 -20.0%	N/A	+55.7%	$2.60M	$388K	N/A	40	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HEPA) was last updated on 8/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hepion Pharmaceuticals (HEPA) Competitors

HEPA vs. GRI, SXTP, NXTS, VCNX, and CASI

How does Hepion Pharmaceuticals compare to GRI Bio?

Summary

How does Hepion Pharmaceuticals compare to 60 Degrees Pharmaceuticals?

Summary

How does Hepion Pharmaceuticals compare to Nexentis Technologies?

Summary

How does Hepion Pharmaceuticals compare to Vaccinex?

Summary

How does Hepion Pharmaceuticals compare to CASI Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEPA vs. The Competition

Hepion Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hepion Pharmaceuticals (HEPA) Competitors

HEPA vs. GRI, SXTP, NXTS, VCNX, and CASI

How does Hepion Pharmaceuticals compare to GRI Bio?

Do institutionals and insiders have more ownership in GRI or HEPA?

Is GRI or HEPA more profitable?

Do analysts rate GRI or HEPA?

Which has preferable valuation and earnings, GRI or HEPA?

Does the media refer more to GRI or HEPA?

Which has more volatility & risk, GRI or HEPA?

Summary

How does Hepion Pharmaceuticals compare to 60 Degrees Pharmaceuticals?

Which has more volatility & risk, HEPA or SXTP?

Does the media refer more to HEPA or SXTP?

Do institutionals & insiders believe in HEPA or SXTP?

Do analysts recommend HEPA or SXTP?

Which has preferable valuation & earnings, HEPA or SXTP?

Is HEPA or SXTP more profitable?

Summary

How does Hepion Pharmaceuticals compare to Nexentis Technologies?

Does the media favor HEPA or NXTS?

Which has more risk and volatility, HEPA or NXTS?

Do insiders & institutionals have more ownership in HEPA or NXTS?

Do analysts prefer HEPA or NXTS?

Is HEPA or NXTS more profitable?

Which has higher valuation and earnings, HEPA or NXTS?

Summary

How does Hepion Pharmaceuticals compare to Vaccinex?

Which has preferable earnings and valuation, VCNX or HEPA?

Which has more risk & volatility, VCNX or HEPA?

Is VCNX or HEPA more profitable?

Do insiders & institutionals hold more shares of VCNX or HEPA?

Does the media prefer VCNX or HEPA?

Summary

How does Hepion Pharmaceuticals compare to CASI Pharmaceuticals?

Does the media refer more to CASI or HEPA?

Do analysts prefer CASI or HEPA?

Do insiders & institutionals believe in CASI or HEPA?

Which has stronger earnings & valuation, CASI or HEPA?

Which has more volatility & risk, CASI or HEPA?

Is CASI or HEPA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEPA vs. The Competition

Hepion Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools